[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356378-105":59,"doc-detail-356378-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-and-validation-of-gene-expression-based-signature-for-high-grade-serous-ovarian-cancer","Development and validation of gene expression-based signature for high-grade serous ovarian cancer","","High-grade serous ovarian cancer (HGSOC) is a highly lethal gynecologic malignancy often diagnosed at late stages because reliable early-detection strategies are limited. Existing ovarian cancer biomarkers lack specificity and do not provide adequate diagnostic or prognostic performance. A two-step machine learning workflow was used to discover candidate biomarkers in TCGA and GTEx cohorts and then validate selected genes in an external clinically annotated tissue cohort to evaluate classification of HGSOC versus benign conditions and predict overall survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-and-validation-of-gene-expression-based-signature-for-high-grade-serous-ovarian-cancer/356378/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-and-validation-of-gene-expression-based-signature-for-high-grade-serous-ovarian-cancer/356378.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are new biomarkers needed for high-grade serous ovarian cancer?","Question",{"text":112,"@type":113},"HGSOC is often diagnosed late due to insufficient early-detection strategies, and existing biomarkers do not provide specific diagnostic or prognostic accuracy for ovarian cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were potential biomarkers identified and validated in the study?",{"text":117,"@type":113},"The study used a two-step machine learning approach on TCGA and GTEx ovarian cohorts, then validated the selected genes in an external clinically annotated tissue cohort of 65 samples.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the 10-gene signature achieve in distinguishing HGSOC and predicting outcomes?",{"text":121,"@type":113},"The ten-gene signature separated HGSOC from benign gynecologic conditions, with GRB7 showing the highest ROC AUC (0.986). It also predicted 5-year survival in the tissue cohort (AUC = 0.815).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356378,1790173951,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Vaicekauskaitė et al. Journal of Ovarian Research (2026) 19:68 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-026-01989-z](https://doi.org/10.1186/s13048-026-01989-z)  \nRESEARCH Open Access  \nDevelopment and validation of gene expression-based signature for high-grade serous ovarian cancer  \nIeva Vaicekauskaitė1,2, Julius Juodakis3, Paulina Kazlauskaitė 1, Rūta Čiurlienė4, Giedrė Smailytė1, Juozas Rimantas Lazutka2 and Rasa Sabaliauskaitė1,2*  \nAbstract  \nBackground High-grade serous ovarian cancer (HGSOC) is the second most lethal gynecologic malignancy,  \noften diagnosed at a late stage due to the lack of reliable early detection strategies. Currently, there are no specific diagnostic or prognostic biomarkers for ovarian cancer (OC) . Thus, there is a great need for novel validated biomarkers for OC diagnosis.  \nMethods A two-step machine learning approach was employed to identify potential HGSOC biomarkers in The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression project (GTEx) ovarian cohorts. The selected genes were then validated in an external, clinically annotated tissue cohort of 65 samples from OC patients, treated in Lithuania, to assess biomarker performance in separating HGSOC from benign gynecologic conditions and predict overall survival.  \nResults A ten-gene signature (EXO1, RAD50, PPT2, LUC7L2, PKP3, CDCA5, ZFPL1, VPS33B, GRB7, and TCEAL4) was selected for further analysis in the external cohort. Expression of each of the ten genes was highly indicative of HGSOC compared to benign gynecologic conditions (p ≤0. 030) and separated these groups with GRB7 expression reaching the highest area under the ROC curve (AUC) of 0.986. RAD50, VPS33B, and ZFPL1 expression also correlated with stage in HGSOC cases (p \u003C 0. 042), while TCEAL4 expression was associated with tumor grade (p = 0 . 038) . The 10-gene signature was also predictive of 5-year survival in the OC tissue cohort (AUC = 0 . 815) .  \nConclusions The ten selected gene expression biomarkers could be useful for HGSOC diagnosis and prognosis; however, further investigations in their prediction of OC patients’ survival are still required.  \nKeywords High-grade serous ovarian carcinoma, Ovarian cancer, Gene expression, Diagnostic model  \n*Correspondence:  \nRasa Sabaliauskaitė  \n[rasa.sabaliauskaite@gmc.vu.lt](rasa.sabaliauskaite@gmc.vu.lt)  \n1National Cancer Institute, Vilnius, Lithuania  \n2Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania  \n3Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 4Vilnius University Hospital Santaros Clinics, National Cancer Centre, Vilnius, Lithuania  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nVaicekauskaitė et al. Journal of Ovarian Research (2026) 19:68  \nIntroduction  \nOvarian cancer (OC) is the second ","cbCaidtF4v2FKU95","https://ap.wps.com/l/cbCaidtF4v2FKU95","pdf",3152338,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why are new biomarkers needed for high-grade serous ovarian cancer?\",\"answer\":\"HGSOC is often diagnosed late due to insufficient early-detection strategies, and existing biomarkers do not provide specific diagnostic or prognostic accuracy for ovarian cancer.\"},{\"question\":\"How were potential biomarkers identified and validated in the study?\",\"answer\":\"The study used a two-step machine learning approach on TCGA and GTEx ovarian cohorts, then validated the selected genes in an external clinically annotated tissue cohort of 65 samples.\"},{\"question\":\"What does the 10-gene signature achieve in distinguishing HGSOC and predicting outcomes?\",\"answer\":\"The ten-gene signature separated HGSOC from benign gynecologic conditions, with GRB7 showing the highest ROC AUC (0.986). It also predicted 5-year survival in the tissue cohort (AUC = 0.815).\"}]","Development and validation of gene expression-based signature for high-grade serous ovarian cancer | PDF",1790125093,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93ccc8e8b467c2a0a0b110b5a0ad11e4.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bc27101f8aadc7e64f625d84df7d1bc.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e87fb5a0ae8c3125b86b30a031445fe0.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6422ca19596fcbd6923684f729835a70.webp",980,1306]